{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:08:00Z","timestamp":1781730480524,"version":"3.54.5"},"reference-count":28,"publisher":"American Psychiatric Association Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[1999,2,1]]},"DOI":"10.1176\/ajp.156.2.294","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:17:10Z","timestamp":1659111430000},"page":"294-298","source":"Crossref","is-referenced-by-count":155,"title":["Clozapine and Risperidone in Chronic Schizophrenia: Effects on Symptoms, Parkinsonian Side Effects, and Neuroendocrine Response"],"prefix":"10.1176","volume":"156","author":[{"given":"Alan F.","family":"Breier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Ping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra A.","family":"Pinals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Elman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb M.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Todd","family":"Lafargue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Clifton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pickar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R15602BABEAHHB","unstructured":"Meltzer HY, Matsubara S, Lee J-C: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251:238\u2013249"},{"key":"R15602BABEABJD","doi-asserted-by":"crossref","unstructured":"Schotte A, Janssen PE, Gommeren W, Luyten WH, Van Bompel P, Lesage LS, De Loore K, Levsen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124:57\u201373","DOI":"10.1007\/BF02245606"},{"key":"atypb1","unstructured":"Leysen JE, Grommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ: Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247:661\u2013670"},{"key":"R15602BABCEJBB","doi-asserted-by":"crossref","unstructured":"Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharma\u00adcology 1996; 14:87\u201396","DOI":"10.1016\/0893-133X(94)00129-N"},{"key":"R15602BABDFHBA","doi-asserted-by":"crossref","unstructured":"Casey DE: Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys. Psychopharmacology (Berl) 1996; 124:134\u2013140","DOI":"10.1007\/BF02245613"},{"key":"R15602BABDJEGD","doi-asserted-by":"crossref","unstructured":"Lamberts SW, van Koetsveld PM, Hofland LJ: The effect of clozapine on prolactin secretion at the level of the lactotroph. Life Sci 1990; 46:1013\u20131019","DOI":"10.1016\/0024-3205(90)90025-M"},{"key":"R15602BABBCCCE","doi-asserted-by":"crossref","unstructured":"Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S: Clozapine: plasma levels and prolactin response. Psychopharmacology (Berl) 1981; 72:184\u2013187","DOI":"10.1007\/BF00429215"},{"key":"R15602BABCCCJE","doi-asserted-by":"crossref","unstructured":"Kinon BJ, Lieberman JA: Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996; 124:2\u201334","DOI":"10.1007\/BF02245602"},{"key":"R15602BABDDCEB","doi-asserted-by":"crossref","unstructured":"Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799\u2013812","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"R15602BABCHJJA","doi-asserted-by":"crossref","unstructured":"Andreasen NC: Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982; 39:784\u2013788","DOI":"10.1001\/archpsyc.1982.04290070020005"},{"key":"R15602BABBBAFD","doi-asserted-by":"crossref","unstructured":"Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11\u201319","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"R15602BABDFJGB","doi-asserted-by":"crossref","unstructured":"Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56\u201362","DOI":"10.1136\/jnnp.23.1.56"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"Phillips L: Case history data and prognosis in schizophrenia. J Nerv Ment Dis 1953; 117:515\u2013525","DOI":"10.1097\/00005053-195306000-00004"},{"key":"R15602BABBJFJJ","doi-asserted-by":"crossref","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789\u2013796","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"R15602BABDCDFG","doi-asserted-by":"crossref","unstructured":"Pickar D, Owen RR, Litman RE, Konicki F, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345\u2013353","DOI":"10.1001\/archpsyc.1992.01820050009001"},{"key":"R15602BABBBHGJ","doi-asserted-by":"crossref","unstructured":"Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20\u201326","DOI":"10.1176\/ajp.151.1.20"},{"key":"R15602BABCCAEA","doi-asserted-by":"crossref","unstructured":"Meltzer HY, Bernett S, Bastani B, Ramirez LF: Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41:892\u2013897","DOI":"10.1176\/ps.41.8.892"},{"key":"R15602BABDADAC","doi-asserted-by":"crossref","unstructured":"Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport J: Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53:1090\u20131097","DOI":"10.1001\/archpsyc.1996.01830120020005"},{"key":"R15602BABCBJIJ","doi-asserted-by":"crossref","unstructured":"Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825\u2013835","DOI":"10.1176\/ajp.151.6.825"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Claus A, Bollen J, DeCuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85:295\u2013305","DOI":"10.1111\/j.1600-0447.1992.tb01473.x"},{"key":"R15602BABCHHHA","doi-asserted-by":"crossref","unstructured":"Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25\u201340","DOI":"10.1097\/00004714-199302000-00004"},{"key":"R15602BABBBIJB","doi-asserted-by":"crossref","unstructured":"Mattes JA: Risperidone: how good is the evidence for efficacy? Schizophr Bull 1997; 23:155\u2013161","DOI":"10.1093\/schbul\/23.1.155"},{"key":"R15602BABDBDHA","doi-asserted-by":"crossref","unstructured":"Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielson M, Salvesen I: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88:395\u2013402","DOI":"10.1111\/j.1600-0447.1993.tb03480.x"},{"key":"R15602BABDBFIA","doi-asserted-by":"crossref","unstructured":"Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA: Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152:827\u2013832","DOI":"10.1176\/ajp.152.6.827"},{"key":"R15602BABCHCDF","doi-asserted-by":"crossref","unstructured":"Lindenmayer J-P, Grochowski S, Mabugot L: Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1994; 14:201\u2013204","DOI":"10.1097\/00004714-199406000-00008"},{"key":"R15602BABEBHJJ","doi-asserted-by":"crossref","unstructured":"Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P, Risperidone Study Group: Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998; 155:499\u2013504","DOI":"10.1176\/ajp.155.4.499"},{"key":"R15602BABCFHBD","doi-asserted-by":"crossref","unstructured":"Pickar D, Su T-P, Weinberger DR, Coppola R, Malhotra AK, Knable MB, Lee KS, Gorey J, Bartko JJ, Breier A, Hsiao J: Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients. Am J Psychiatry 1996; 153:1571\u20131578","DOI":"10.1176\/ajp.153.12.1571"},{"key":"R15602BABBFJIF","doi-asserted-by":"crossref","unstructured":"Farde L, Nordstrom A-L, Wiesel F-A, Pauli S, Halidin C, Sedvall G: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538\u2013544","DOI":"10.1001\/archpsyc.1992.01820070032005"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ajp.psychiatryonline.org\/doi\/10.1176\/ajp.156.2.294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T21:40:36Z","timestamp":1722375636000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/ajp.156.2.294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,2,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,2,1]]}},"alternative-id":["10.1176\/ajp.156.2.294"],"URL":"https:\/\/doi.org\/10.1176\/ajp.156.2.294","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,2,1]]}}}